24.05.2005 – 22:05
Three Rivers Pharmaceuticals Announces Acquisition of Worldwide Rights to Amphotec(R)/Amphocil(R)
Cranberry Township, Pennsylvania (ots/PRNewswire)
Three Rivers Pharmaceuticals, LLC announced today that it has completed the acquisition of worldwide ownership of Amphotec(R)/Amphocil(R) (amphotericin B cholesteryl sulfate complex for injection) from InterMune, Inc. (Nasdaq: ITMN). Amphotec is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immunocompromised patients. Financial terms of the agreement, which was signed and executed on May 20, 2005, were not disclosed.
"Three Rivers Pharmaceuticals is very pleased to be acquiring Amphotec from InterMune," stated Donald J. Kerrish, RPh, President and CEO of Three Rivers Pharmaceuticals. "This product is a welcome addition to our offering of specialty pharmaceuticals and will allow Three Rivers to continue its commitment to providing the highest standards of quality and customer care."
"Because invasive aspergillosis falls outside of InterMune's two areas of therapeutic focus, hepatology and pulmonology, we decided it was in the best interest of both shareholders and patients to divest this product," stated Dan Welch, InterMune's President and CEO. "We believe Three Rivers Pharmaceuticals has the right portfolio and areas of expertise to fully and successfully commercialize this product."
About Three Rivers Pharmaceuticals
Three Rivers Pharmaceuticals is a privately owned company located in Cranberry Township, PA. Three Rivers Pharmaceuticals' mission is to develop and market specialty prescription drugs for diseases that have a significant national and worldwide impact. The company is dedicated to providing public education, disease state management programs, and improving patient access to high quality, lower cost pharmaceutical products. For additional information about Three Rivers Pharmaceuticals, please visit www.3riverspharma.com .
InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. In addition to the currently marketed product indicated for the treatment of chronic hepatitis C virus (HCV) infections, three-times-a-week Infergen(R) (interferon alfacon-1), InterMune has a broad and deep late-stage product portfolio addressing HCV infections, particularly nonresponders, or those patients who do not respond to first-line therapy, and idiopathic pulmonary fibrosis (IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen plus ribavirin, and a Phase IIb trial of daily Infergen plus Actimmune(R) (interferon gamma-1b) with and without ribavirin for the treatment of HCV patients who do not respond to first-line therapy. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. The pulmonology portfolio includes pirfenidone and Actimmune. Pirfenidone is being developed for the treatment of IPF. Actimmune is being investigated in the INSPIRE Trial, a Phase III study in patients with IPF. For additional information about InterMune and its development pipeline, please visit www.intermune.com .
ots Originaltext: Three Rivers Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.ch
Paul F. Fagan, Esq., Executive Vice-President and General Counsel of
Three Rivers Pharmaceuticals, +1-800-405-8506, or